So in conclusion, many drugs protect against anti-tuberculosis-induced liver injury by activating Nrf2 and blocking NF-κB, and it is of greater clinical significance to investigate the interaction between Nrf2 and NF-κB. This evidence concerns the gene NFE2L2 and tuberculosis.